Latest

ARM board member Miguel Forte highlights education programs, innovation hubs, and hands-on training to foster workforce expertise in the biopharma industry.

Driven by R&D investment and personalized medicine, advanced biotech equipment is essential for scalable drug production and development into the next decade, according to a BCC Research report.

Maximizing value in advanced therapies requires the use of proven approaches, expert logistics, and tailored distribution, says Miguel Forte, board member of ARM.

Groundbreaking gene delivery, scalable IPSC approaches, and advanced production solutions will impact future CGT development, according to ARM board member, Miguel Forte.

Biopharma Q3 2025 data show M&A strength, selective venture capital favoring Phase II, record obesity deals, and significant upfronts flowing toward innovation in China.

As cell and gene therapy is poised to play a major role in the future of medicine, it’s important to know the basics.

ARM Board Member Miguel Forte highlights CGT investment shifts, sector resilience, and alternative funding strategies during Meeting on the Mesa.

Boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development are top of mind for life science CEOs.

Cellevate’s nanofiber technology enables higher viral vaccine titers in adherent cell cultures, advancing efficiency in large-scale biomanufacturing.

Each step of development and manufacturing is becoming more interconnected, and BioPharm's September/October issue highlights the strategies, tools, and innovations shaping the future of the field.

US President Donald Trump confirmed AstraZeneca as the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.

This second part of a two-part article provides a clear understanding of microbiological load reduction during cleaning processes in the non-sterile pharmaceutical manufacturing.

Scaling biopharma innovation demands advanced manufacturing, global market expansion, and solving patient access barriers.